Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Stocks soured by Wall Street sell-off and 'vaccine nationalism'

Thu, 28th Jan 2021 09:11

* Asian stock markets : https://tmsnrt.rs/2zpUAr4

* Easyjet highlights pain of airlines during lockdown

* Talk of distressed selling by hedge funds as shorts
squeezed

* Dollar gets safe-haven bid as euro backtracks

By Huw Jones

LONDON, Jan 28 (Reuters) - Shares wiped out their gains in
Europe for the year early on Thursday, soured by a sell-off on
Wall Street, no end in sight to pandemic lockdowns and a squeeze
in short positions.

The pan-European STOXX benchmark was down 1.8% at
395.77 points, its lowest since December. London, Paris
and Frankfurt all fell.

"The initial optimism of early this year is starting to
dissipate because of the prospects of tighter pandemic
restrictions for longer, and concerns over 'vaccine
nationalism'," said Michael Hewson, chief market analyst at CMC
Markets.

The European Union, locked in a public spat with vaccine
producer AstraZeneca, wants a shortfall in the company's
supplies to the bloc topped up from production in Britain.

Easyjet shares fell 2.3% after the airline warned it
would fly no more than 10% of 2019's capacity, highlighting the
plight of sectors hit by lengthy lockdowns.

The move by investors into "reflation" trades at the start
of the year on then-brighter growth prospects now looked
premature, analysts said.

"Amid concerns about the speed of vaccine distribution and
the COVID-19 impact on economic growth recovery, cyclical credit
looks most likely to underperform," UniCredit analysts said.

Wall Street on Wednesday suffered its biggest one-day
percentage drop in three months as the S&P500 index and Nasdaq
Composite fell 2.6%.

Some pointed a finger at U.S. retail investors who had
forced a massive squeeze on hedge funds that held short
positions in stocks such as GameStop.

"We could see much more choppiness and much more volatility.
We have a bit of a perfect storm heading into the month end,
which is weighing on equity markets, but I don't think at the
moment we are in a place where it's going to come crashing off,"
Hewson said.

On the data front, analysts said the focus will be on German
inflation figures and fourth-quarter U.S. economic growth.

Yields on the 10-year U.S. Treasury bond fell
below 1% for the first time in three weeks overnight in a
further sign of a shrinking demand for risk.

ASIA WEAKER

Asian shares slid on Thursday while the safe-haven dollar
rallied as Wall Street's sell-off and delays in coronavirus
vaccines provided an excuse to book profits on recent gains.

MSCI's broadest index of Asia-Pacific shares outside Japan
fell 2%, with valuations looking stretched after
the index rose more than 6% just this month.

Japan's Nikkei fell 1.5%, its sharpest drop since
October, and Chinese blue chips lost 2.7% as liquidity
tightened before the Lunar New Year holidays.

South Korea fell 1.7%, led by losses in Samsung
after it reported earnings.

Even the tech darlings were not immune. Facebook
dropped despite reporting earnings well above expectations.
Apple Inc also handily beat forecasts, but its shares
lost 3% after the bell.

Dealers noted the market had focused more on a downbeat
economic outlook from the Federal Reserve overnight than on its
pledge of continued policy support.

The safe-haven U.S. dollar gained, with its index up at
90.771 from a January low of 89.206.

The euro fell to $1.2093 amid reports the European
Central Bank felt markets were under-pricing the risk of more
rate cuts.

The bounce in the dollar kept gold prices soft around $1,837
an ounce.

Global demand concerns restrained oil prices despite a drop
in U.S. crude stocks. U.S. crude fell 34 cents to $52.51
a barrel. Brent crude futures dropped to $55.50.

(Additional reporting by Alwyn Scott; editing by Christian
Schmollinger, Ana Nicolaci da Costa, Larry King)

More News
24 Oct 2023 17:08

LONDON MARKET CLOSE: FTSE 100 shakes off midday losses after US data

(Alliance News) - The FTSE 100 closed in the green on Tuesday following positive private sector data out of the US, despite figures closer to home showing a weaker UK private sector and rising unemployment.

Read more
24 Oct 2023 11:06

AstraZeneca says US accepts self-administered flu vaccine for review

(Alliance News) - AstraZeneca PLC on Tuesday said the US health watchdog has approved a review for its FluMist Quadrivalent self-administered flu vaccine, for which the drugmaker is seeking a green light.

Read more
23 Oct 2023 17:50

AstraZeneca celebrates drug trial results for cancer indications

(Alliance News) - AstraZeneca PLC on Monday said new drugs, developed in partnership with Daiichi Sankyo Co Ltd, showed positive results in patients with solid tumours, lung and breast cancer.

Read more
23 Oct 2023 17:08

LONDON MARKET CLOSE: Stocks largely down on Middle East hostilities

(Alliance News) - Stock prices in London closed largely lower on Monday, as investors were unable to shake off concerns surrounding the conflict in the Middle East, while developments in the US bond market added to the drama.

Read more
23 Oct 2023 08:45

TOP NEWS: AstraZeneca says Enhertu approved by European Commission

(Alliance News) - AstraZeneca PLC on Monday said its Enhertu treatment has been approved by the European Commission to treat adult lung cancer patients.

Read more
23 Oct 2023 07:46

LONDON BRIEFING: Keller expects higher profit; Upland rejects approach

(Alliance News) - Stocks in London are set to open slightly higher on Monday, as risk sentiment improves after a difficult period for markets last week.

Read more
18 Oct 2023 09:04

AstraZeneca drug Solaris approved in China as NMOSD treatment

(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder

Read more
17 Oct 2023 12:06

LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms

(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.

Read more
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.